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Eosinophilic esophagitis (EoE) is a chronic, immune/antigen-
mediated esophageal disease affecting both children and 
adults. The condition is characterized by an eosinophilic infil-
tration of the esophageal epithelium. Symptoms of esopha-
geal dysfunction include dysphagia, food impaction and 
symptoms mimicking gastroesophageal reflux disease. Endo-
scopic examination typically reveals mucosal fragility, ring or 
corrugated mucosa, longitudinal furrows, whitish plaques or 
a small caliber esophagus. Histologic findings of >15 eosino-
phils per high-power field is the diagnostic hallmark of EoE. 
An elimination diet, topical corticosteroids or endoscopic di-
lation for fibrostenotic disease serve as effective therapeutic 
option. (Gut Liver 2014;8:590-597)
Key Words: Eosinophilic esophagitis; Gastroesophageal re-
flux; High-power field
INTRODUCTION
The occurrence of eosinophilic esophagitis (EoE) has increased 
recently and has become increasingly recognized in the past de-
cade in Western countries. Since the mid-1990s, EoE has been 
diagnosed by both gastroenterologists and allergy specialists 
and EoE has rapidly emerged as a distinct disease entity in both 
pediatric and adult gastroenterology, and the studies of EoE 
have increased in number.1-3 However, only limited studies has 
been published in Asian countries including Korea.4,5 
In this paper, we discuss the data published mainly within the 
last 5 years on the epidemiology, pathogenesis, clinical symp-
toms, diagnosis, treatment, and prognosis of EoE.
EPIDEMIOLOGY
It is debatable whether the reason for the recent high preva-
lence of EoE is a real increase in the incidence or increased di-
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agnosis due to increased awareness about the disease. However, 
a recently published 20-year prospective, population-based 
study from Switzerland in the absence of EoE awareness pro-
gram suggests actual increase in EoE’s incidence and prevalence 
(Table 1).6 In a retrospective study in all patients from a Aus-
tralian provincia city with otherwise unexplained eosinophillic 
inflammation of the squamous epithelium, no diagnosis of EoE 
was made between 1981 and 1994 but 12 patients were diag-
nosed between 1995 and 2000 and 19 patients between 2001 
and 2002 indicating a clear increase in incidence of EoE in this 
area.7 It is estimated that EoE in Westernized countries affects 
between 40 and 55 individuals per 100,000 population, similar 
to that of Crohn’s disease.3
Recent meta-analysis studies that surveyed the papers pub-
lished in English from 1978 to 2005 show the male-to-female 
ratio of 3:1 with most subjects being in the 30s and 40s.8,9 In a 
Table 1. Eosinophilic Esophagitis Incidence and Cumulative Preva-
lence (95% CIs) Evaluated in 3-Year Intervals
3-yr interval
Incidence per 100,000 
inhabitants  
(95% CI)
Cumulative prevalence  
per 100,000 inhabitants 
(95% CI)
1989–1991 1.2 (0.25–3.52) 3.6 (0.75–10.56)
1992–1994 1.6 (0.42–3.98) 7.9 (3.27–16.77)
1995–1997 1.1 (0.24–3.36) 11.5 (5.51–21.14)
1998–2000 0.7 (0.09–2.74) 12.5 (7.05–23.82)
2001–2003 0.7 (0.09–2.71) 13.4 (8.60–26.40)
2004–2006 4.4 (2.30–7.77) 26.6 (18.89–42.38)
2007–2009 7.4 (4.48–11.34) 42.8 (36.96–67.33)
Incidence is reported per 100,000 inhabitants per year as the mean of 
a 3-year interval. Cumulative prevalence was calculated per 100,000 
inhabitants at the end of the time interval. Adapted from Hruz P, et 
al. J Allergy Clin Immunol 2011;128:1349-1350.e5, with permission 
from Elsevier.6 
CI, confidence interval.
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prospective study conducted in the United States, 31 patients 
with esophageal food impaction were evaluated for 3 years. 
Seventeen of 31 patients (54.8%) had >20 eosinophils/high-
power field [HPF] without gender predilection.7
EoE was diagnosed in 3.4% of children with reflux symp-
toms1 and 6.8% of children with reflux esophagitis.8 In addition, 
EoE showed a higher prevalence of 68% to 94% in children 
with reflux symptoms not responding to proton pump inhibitors 
(PPIs).10-12
PATHOPHYSIOLOGY/PATHOGENESIS
EoE is an immune/antigen-mediated disease in which food 
or environmental antigens stimulate an inflammatory response. 
EoE is frequently associated with allergy, although the causal 
relationship is not known. Rates of allergic rhinitis, asthma, and 
eczema in patients with EoE range from 40% to 75%, 14% to 
70%, and 4% to 60%, respectively.3,13,14 The percentage of male 
in adults and pediatric patients is similar, 75% and 73%, respec-
tively, while the incidence of atopic diseases including asthma, 
atopic dermatitis, and food allergy are more common (51% to 
84%) in children than in adult patients with EoE (29% to 60%) 
although these diseases are prevalent in both pediatric and adult 
patients.14
In addition, seasonality associated with EoE suggests that 
aeroallergen may play a role in the pathogenesis of EoE.3,13 Ap-
proximately 53% to 73% of patients with EoE are positive on 
the skin prick test, which is associated with exogenous allergic 
reactions related to serum immunoglobulin E (IgE).14 However, 
the fact that 27% to 47% of patients displayed a negative skin 
prick test may indicate a role of endogenous nonallergic mecha-
nisms leading to eosinophil infiltration unrelated to IgE.9 
Eosinophilic infiltration has been reported to be related to 
key cytokines, such as interleukin (IL)-4, IL-5, IL-13, and eo-
taxin,15-17 which stimulate the production of eotaxin-3, a potent 
chemokine in the esophageal mucosa. In turn, eotaxin-3 re-
cruits and activates eosinophils to secrete proinflammatory and 
profibrotic mediators. IL-5 activates eosinophils, which in turn 
release transforming growth factor b stimulating fibroblasts and 
inducing fibrosis. IL-13 upregulates eotaxin-3, which recruits 
eosinophils in esophageal mucosa. In animal models, intratra-
cheal administration of IL-13 induced infiltration of eosinophils 
in esophageal mucosa. In other words, these mediators cause 
eosinophilic infiltration, local tissue damage, perturb inflam-
matory response, and induce fibrosis, resulting in esophageal 
remodeling and dysfunction.17,18
CLINICAL FEATURES
The main clinical symptoms are vomiting, dysphagia, and ab-
dominal pain in children, whereas dysphagia with food impac-
tion is common in adults (Table 2).3 Less common symptoms in 
adults are heartburn, noncardiac chest pain, odynophagia, and 
vomiting.3,13 Peripheral eosinophilia appears in about 60% of 
pediatric patients and 5% to 50% of adult patients.19 Increased 
serum IgE, skin prick test and positive radioallergosorbent test 
result are observed in 40% to 73% of patients.3,14 Normal 24-
hour esophageal pH monitoring pattern is observed in more 
than 90% of pediatric patients and 85% to 100% of adult pa-
tients.14
DIAGNOSIS
EoE can be diagnosed if eosinophilic infiltration is found 
in esophageal epithelium. Eosinophils are not present in nor-
mal appearing mucosa, but eosinophilic infiltration can occur 
from various diseases, such as gastroesophageal reflux disease 
(GERD), eosinophilic gastroenteritis, collagen vascular disease, 
achalasia, and parasitic infections.20,21 The presence of allergic 
history, appropriate clinical symptoms and endoscopic findings, 
and histopathologic findings are helpful in excluding other dis-
eases. Few eosinophils can be observed in the mucosa (≤4 per 
HPF) in GERD but typical endoscopic appearance of EoE such 
as longitudinal furrows may not be seen in GERD. GERD is usu-
ally responsive to acid suppression but nonresponsive to steroid 
therapy.22 
In 2011, diagnostic guidelines were updated.13 These included 
the followings: 1) symptoms related to esophageal dysfunction; 
2) ≥15 eosinophils per HPF in at least one esophageal biopsy 
specimen, with few exceptions; 3) eosinophilia limited to the 
esophagus; and 4) other causes of esophageal eosinophilia 
excluded, particularly PPI-responsive esophageal eosinophilia 
(PPI-REE) (Table 3).13 Several studies have shown that more 
than one-third of patients with esophageal eosinophilia respond 
to PPI treatment. However, it is unknown whether PPI-REE is a 
separate, new disease entity, an atypical manifestation of GERD, 
or a variant form of EoE that responds to PPI. In 2012, Dellon21 
suggested a novel diagnostic algorithm for EoE (Fig. 1), in which 




“GERD refractory to medical management” “GERD refractory to 
medical management”
“GERD refractory to surgical management”




Adapted from Furuta GT, et al. Gastroenterology 2007;133:1342-
1363, with permission from Elsevier.3
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EoE must be suspected clinically at first followed by endoscopy 
with biopsy. To differentiate the other causes of esophageal 
eosinophilia, in particular GERD or PPI-REE, endoscopy with 
biopsy is recommended after a trial of PPI for 8 weeks.
1. Endoscopic findings
A number of studies have reported several typical endoscopic 
features of EoE: fixed esophageal rings (corrugated rings or tra-
chealinization), transient esophageal rings (felinization), whitish 
exudate or papules, longitudinal furrows, small/narrow-caliber 
esophagus, and mucosal laceration induced by passage of en-
doscope (fragile crêpe paper-like appearance).8,23 We previously 
studied the concordance rate and clinical predictors of EoE in 
endoscopically suspected eosinophilic esophagitis (EsEoE).23 Of 
17 patients with EsEoE, five were finally confirmed as EoE by 
histology (diagnostic concordance rate, 29.4%).  In a study by 
Sgouros et al.,9 normal endoscopic finding was observed in only 
8.8% of the patients with EoE. 
The most common endoscopic findings of EoE are mucosal or 
linear sheering after the passage of the endoscope (59.3%), rings 
or corrugated esophagus (49.2%), strictures (39.7%), whitish 
exudates or papules (15.7%), and narrow/small-caliber esopha-
gus (5.3%).8 Additionally, longitudinal furrows, diminished/
lost vascularity, and fragile crêpe paper-like appearance are 
observed. Longitudinal furrow, as shown in Fig. 2, was the most 
common endoscopic finding (6/9, 66.7%), and only one of nine 
patients with EoE presented normal looking mucosa (11.1%).23 
We concluded that patients with dysphagia with two or more of 
the aforementioned endoscopic findings were more suggestive 
of EoE. However, we did not find positive correlation between 
eosinophil density in biopsy specimens, clinical symptoms, and 
endoscopic features.
Endoscopic ultrasonography (EUS) reveals that longitudinal 
furrows present as topographical changes caused by thicken-
ing of mucosa and submucosa.24 Thickened esophageal wall 
combined with mucosa, submucosa, and muscularis propria was 
found in EoE using EUS. Therefore, causes of dysphagia and/
or food impaction may be explained by thickened muscle layer 
consisting of muscular dysfunction. 
2. Histopathologic features
EoE is characterized by a dense eosinophilic infiltrate into the 
Table 3. Rationale for the Definition of and Diagnostic Guidelines for Eosinophilic Esophagitis
1. Change in EE abbreviation. EE often has been used as an abbreviation for erosive esophagitis. Use of the abbreviation EoE rather than EE for 
eosinophilic esophagitis should eliminate the potential for confusion.
2. Inclusion of the word chronic. Clinical experience supports that EoE is a chronic disease that will require long-term follow-up and treatment.
3. Inclusion of the term immune/antigen driven. An increasing body of clinical, translational, and basic evidence supports a role of an aberrant 
immune response (potentially reversible with treatment) as an underlying pathogenetic feature of EoE.
4. Continued use of the word clinicopathologic. No biomarker or pathognomonic element has been identified that would eliminate the need for 
both symptoms and an abnormal histology to make the diagnosis.
5. No change in threshold number of 15 eosinophils/HPF. Since the 2007 CR, no studies have identified a clear ‘‘lower limit of esophageal eo-
sinophilia’’ or threshold number that would define EoE or have identified other histologic features or pattern of disease distribution that are 
pathognomonic of EoE.
6. No change in the use of HPF as the unit of measurement for eosinophilia. No studies have yet determined a standardized size of an HPF, and 
this might be practically unachievable. This issue is problematic because the size of an HPF can alter the reported number of eosinophils per 
HPF.
7. Inclusion of topical steroids/diet exclusions as a treatment. Current clinical evidence exists to include this paradigm to differentiate EoE from 
other diseases. Other potential therapies might exist but have not yet been supported in the literature.
8. Exclusion of GERD reference. A number of other causes of esophageal eosinophilia have been identified, and a broader statement has been 
included that allows for clinical discretion to be used.
9. Inclusion of patients with less than 15 eosinophils/HPF. A small number of patients with EoE (and who are treated with a PPI) might have 
less than the threshold number of eosinophils on their mucosal biopsy specimens associated with other features of eosinophilic inflammation, 
including microabscess formation, superficial layering, or extracellular eosinophil granules. Potential reasons for this finding include but are 
not limited to inadequate biopsy specimens, sampling error, chronic disease, or partial treatment response.
10. Inclusion of the term PPI-responsive esophageal eosinophilia. Therapeutic/basic studies and clinical experience have identified a potential 
anti-inflammatory or barrier-healing role for proton pump inhibition in patients with esophageal eosinophilia.
Adapted from Liacouras CA, et al. J Allergy Clin Immunol 2011;128:3-20.e6, with permission from Elsevier.13
EoE, eosinophilic esophagitis; HPF, high-power field; CR, consensus recommendation; GERD, gastroesophageal reflux disease; PPI, proton pump 
inhibitor.
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Fig. 1. A diagnostic and therapeutic 
algorithm of eosinophilic esopha-
gitis (EoE). Adapted from Dellon 
ES. Clin Gastroenterol Hepatol 
2012;10:1066-1078, with permission 
from Elsevier.21
EGD, esophagogastroduodenoscopy; 
eos, eosinophils; HPF, high-power 
field; PPI, proton pump inhibitor; 
GERD, gastroesophageal reflux 
disease; PPI-REE, PPI-responsive 
esophageal eosinophilia.
Fig. 2. Endoscopic features. (A) Lon-
gitudinal furrows. (B) Furrows and 
rings (spider web-like appearance).
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epithelium of the squamous esophagus, as shown in Fig. 3A. 
To optimize pathologic diagnosis, endoscopic biopsy should be 
taken from the proximal and distal esophagus, since eosinophils 
are not evenly distributed within the esophageal mucosa.21 Eo-
sinophilic infiltration should be absent in gastric and duodenal 
mucosa. The optimal number of biopsies is essential for accurate 
diagnosis. The diagnostic sensitivity of 2, 3, and 6 biopsy speci-
mens are 84%, 97%, and 100%, respectively.13
EoE is also characterized by the formation of microab-
scesses by eosinophil infiltration in the superficial layer of the 
esophageal epithelium, which is observed in 25% to 45% of 
the patients with EoE.25,26 The histologic picture of eosinophilic 
microabscess is shown in Fig. 3B. It is not observed in patients 
with GERD or peptic esophagitis. Infiltration of the superficial 
layer by eosinophils lasts after acid blockade therapy for at 
least 2 months.26 Noncharacteristic findings, such as basal zone 
hyperplasia and increased papillary size are also observed.14 
In our previous study, associated features included degranula-
tion (100%), spongiosis (91.7%), and eosinophilic microabscess 
(58.3%).27
The 2011 diagnostic guideline describes more than 15 eo-
sinophils/HPF in at least one esophageal biopsy specimen, with 
few exceptions, and eosinophilia limited to the esophagus. “Few 
exception” are defined as those patient with <15 eosinophils/
HPF with other features of eosinophilic inflammation including 
microabscess formation, superficial layering or extracellular eo-
sinophil granules.13
3. Esophageal motility studies
The esophageal functions have been studied by barium 
esophagogram, EUS, manometry, and impedance planimetry. 
Esophageal manometic studies detect esophageal motility dis-
orders related to EoE. Incordination of esophageal contraction 
(30%), incomplete relaxation of lower esophageal sphincter, 
excessive contraction of the esophagus (7%), and ineffective 
peristalsis (4%) were mainly observed.9 In addition, tertiary 
esophageal contractions, aperistalsis, multipeaked contractions, 
diffuse spasm are also frequently observed. About 40% of pa-
tients had shown normal manometric findings. Therefore, there 
are no pathognomic findings of manometry for the diagnosis 
of EoE. These esophageal motility disorders occur when eosino-
philic infiltration affects the muscularis propria, in addition to 
mucosal infiltration. 
The recent introduction of high resolution manometry (HRM) 
and impedance planimetry allowed the identification of pane-
sophageal pressurization (by manometry) and changes in esoph-
ageal compliance with decreased distensibility (by impedance 
planimetry).28,29 Roman et al.28 found that 37% of EoE patients 
showed abnormal esophageal motility when HRM was used. The 
most common findings were weak peristalsis and frequent failed 
peristalsis, although these findings were also observed in GERD. 
However, panesophageal pressurization was a specific findings 
in EoE, which represents a manifestation of reduced esophageal 
compliance.
4. Laboratory findings
Peripheral eosinophilia is found in 40% to 50% of patients 
with EoE, and its count decreases after successful treatment 
with topical corticosteroids.3,13 Peripheral eosinophilia is cor-
related with the number of esophageal eosinophils. Serum total 
IgE levels are increased in 50% to 60% of patients with EoE,20,21 
although its level does not reflect either histologic inflammation 
Fig. 3. Histologic findings. (A) Massive infiltration of eosinophils on the esophageal mucosa, >15 eosinophils/high-power field. (B) Eosinophilic 
microabscess (H&E stain, ×200).
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or predictor of therapeutic response. The skin prick test (SPT) 
is an immediate type allergic test for food allergen and aeroal-
lergen.20,21 SPT is warranted in detecting food allergy associated 
with EoE, although the usefulness of therapeutic application 
including specific food avoidance by its positivity is still limited 
and requires more study to validate its significance.
TREATMENTS
It is helpful to identify the algorithmic process for diagnosis 
and proper treatment, prior to undertaking major treatment 
including corticosteroids.21 The goal of the treatment would be 
complete symptom relief and resolution of esophageal eosino-
philia. To exclude other causes of esophageal eosinophilia such 
as GERD and PPI-REE, an 8-week trial of high-dose PPI and re-
peat endoscopy are recommended. PPIs have anti-inflammatory 
effects by reducing eosinophils by decreasing Th2 cytokine-
stimulated eotaxin-3 mRNA expression and protein secretion 
independent of the effects on acid production.30,31 In fact, sev-
eral studies have reported that one-third or more patients with 
esophageal eosinophilia responded to PPI treatment.5 Therefore, 
it has been suggested that PPIs might not distinguish EoE from 
GERD.
If EoE is confirmed, diet therapy and topical corticosteroid to 
suppress immune response will be initiated.32 When evidence 
of fibrostenotic disease, such as narrow-caliber esophagus or 
stricture, is present, endoscopic dilation is effective in improving 
the symptoms. After the treatment, symptoms and eosinophil 
counts are generally improved, but endoscopic findings may not 
be improved, indicating that deformity of esophageal structure, 
or remodeling due to eosinophilic inflammation is irreversible. 
1. Diet
Food allergy has been commonly observed in 15% to 43% 
of subjects with EoE.33 Therefore, it has been suggested that 
identification and elimination of potential food antigens which 
cause antibody response and eosinophilic infiltration would be 
an effective preventive ad therapeutic approaches.13,19,20 SPT and 
patch testing were used to identify the potential food antigens, 
and the patients were advised to avoid positive foods as identi-
fied by these tests. In this study, 18 patients had a concurrent 
improvement in biopsy and clinical response, and six patients 
had partial improvement.34 According to the proposal of Mar-
kowitz and Liacouras,22 the foods that trigger allergy by testing 
or past history should be eliminated and if the food allergens 
are not identified, the foods to which patients are most likely to 
be allergic (i.e., cow’s milk, soy, eggs, wheat, and peanuts) are 
empirically eliminated. 
A diet eliminating milk, egg, soy, wheat, nuts, and seafood 
(six food elimination diet, SFED) has been reported to be an 
effective therapy in EoE. Gonsalves et al.35 demonstrated that 
SFED significantly improved symptoms, endoscopic features, 
and histopathology, and reintroduction of food reproduced EoE 
confirming a role for food allergens.
2. Corticosteroids
The use of steroids is one of the mainstays of pharmacologic 
treatment. Oral corticosteroid therapy improves the symptoms 
within 1 week when administered for 1 month,10 but systemic 
steroids use is associated with side effects. Whereas topical ste-
roids, such as flucatisone and budesonide, known as swallowed 
inhaled steroid therapy, are effective treatments for improve-
ment of symptoms and resolution of esophageal eosinophilia. In 
a study in adults that included 21 patients who were adminis-
tered topical steroids for 6 weeks, all patients had relief of dys-
phagia that lasted a minimum of months.17 Dry mouth was the 
only adverse effect noted and esophageal candidiasis was not 
reported. Three patients relapsed after 4 months.18 Recommend-
ed doses of corticosteroid treatment protocol for EoE are shown 
in Table 4.13 If topical steroids are stopped after initial treatment, 
most of them recurred. But, there is little data regarding the ef-
fectiveness of maintenance treatment. Long-term maintenance 
treatment with low dose budesonide (0.5 mg/day) for 50 weeks 
was more effective than placebo in maintaining EoE in clinical 
and histologic remission,36 although the optimal duration and 
dose of budesonide are not yet clarified.37
3. Leukotriene antagonist, mast cell stabilizer, and other 
biologic drugs
Immunotherapy related to allergic medications includes the 
leukotriene D4 receptor antagonist and anti-IL-5.38 Montelukast, 
a selective inhibitor of the leukotriene D4 receptor, is also used 
Table 4. Recommended Doses of Corticosteroids for Eosinophilic 
Esophagitis
Topical swallowed corticosteroids
Initial doses (see references for preparation and administration in-
formation)
Fluticasone (puffed and swallowed through a metered-dose in-
haler)
Adults: 440–880 mg twice daily
Children: 88–440 mg twice to 4 times daily (to a maximal 
adult dose)
Budesonide (as a viscous suspension)
Children (<10 yr): 1 mg daily
Older children and adults: 2 mg daily
Systemic corticosteroids
For severe cases (e.g., small-caliber esophagus, weight loss, and 
hospitalization)
Prednisone: 1–2 mg/kg
Adapted from Liacouras CA, et al. J Allergy Clin Immunol 2011;128: 
3-20.e6, with permission from Elsevier.13 
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for the treatment of asthma in adults. In a study reported by 
Attwood et al.,39 eight adult patients with EoE was started on 
10 mg per day dose of montelukast but the dose was increased 
up to 100 mg daily if required. Once symptom was relieved, 
the dose was reduced to maintenance levels between 20 and 40 
mg per day. Six of eight patients reported complete subjective 
improvement and five patients remained completely asymptom-
atic. However, the safety of the high dose used in this study is 
unclear.26 Montelukast could not completely treat the infiltration 
of eosinophils in the esophageal tissue.39
Cromolyn sodium, a mast cell stabilizer, is not thought to 
have apparent therapeutic benefit in patients with EoE.38 A 
study conducted with mepolizumab, a humanized monoclonal 
antibody against IL-5, suggested improvement in patient with 
EoE in clinical symptoms, endoscopic findings, and histologic 
findings. However, the long-term effect or safety of this drug 
need to be further investigated.40 Additionally, anti-IL-13 
monoclonal antibodies, antieotaxin-3, anti-IgE antibodies and 
anti-inflammatory drugs have been used either to treat EoE or 
under development.37,38 However, these biologic agents are not 
yet in clinical practice in patients and require further scientific 
evidence.
4. Endoscopic dilation
Endoscopic dilation with balloon is effective for relieving 
symptoms of dysphagia with the evidence of ring or stricture. 
Since it does not affect eosinophilic infiltration and inflamma-
tion, medical therapy and/or dietary therapy should be under-
taken after dilation.21,38 A total of 83% of patients experienced 
immediate symptomatic improvement after esophageal dilation, 
but some patients experienced symptomatic recurrences after 3 
to 8 months in a long-term follow-up.9
NATURAL HISTORY AND PROGNOSIS
EoE is a chronic disease, in which symptoms and inflamma-
tion relapse after cessation of successful treatment, is common.41 
EoE does not seem to limit life expectancy, but impairs the 
quality of life. In an 11.5-year follow-up study, the eosinophilic 
inflammatory process remained confined to the esophagus with-
out transition to eosinophilic gastroenteritis or other disease.42 It 
has not been associated with increased risk of malignant condi-
tions. But many uncertainties still exist, particularly natural his-
tory and prognosis.37
CONCLUSIONS
EoE is a chronic, immune/antigen-mediated esophageal 
disease characterized by eosinophilic infiltration and typical 
clinical presentation includes dysphagia and food impaction 
due to fibrostenosis associated with inflammatory changes and 
alteration of biomechanical properties. Endoscopic examination 
reveals mucosal fragility, longitudinal furrows, ring or corru-
gated mucosa, whitish papules, or small caliber esophagus. After 
exclusion of other causes of esophageal eosinophilia including 
PPI-REE or GERD, the tailored treatment of diet therapy, corti-
costeroids, and/or endoscopic dilation is considered according 
to its phenotype of whether inflammatory and/or fibrostenotic 
changes in the esophagus. Further basic and clinical research 
data are needed to understand its pathophysiology, biomarkers, 
clinical courses and to update the diagnostic algorithm and de-
velop novel treatments.
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